Title :

Lenalidomide is safe and active in waldenstrom macroglobulinemia

Author(s) :

Fouquet, Guillemette [Auteur]
Guidez, Stephanie [Auteur]
Petillon, Marie-Odile [Auteur]
Louni, Chanaz [Auteur]
Ohyba, Bella [Auteur]
Dib, Malek [Auteur]
Poulain, Stephanie [Auteur]
Herbaux, Charles [Auteur]
Martin, Audrey [Auteur]
Thielemans, Beatrice [Auteur]
Brice, Pauline [Auteur]
Choquet, Sylvain [Auteur]
Bakala, Jana [Auteur]
Bories, Claire [Auteur]
Demarquette, Helene [Auteur]
Nudel, Morgane [Auteur]
Tournilhac, Olivier [Auteur]
Arnulf, Bertrand [Auteur]
Legouill, Steven [Auteur]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Banos, Anne [Auteur]
Karlin, Lionel [Auteur]
Salles, Gilles [Auteur]
Leblond, Véronique [Auteur]
Leleu, Xavier [Auteur]

Journal title :

American journal of hematology

Abbreviated title :

Am. J. Hematol.

Volume number :

90

Pages :

1055-1059

Publication date :

2015-11-01

ISSN :

0361-8609

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25 mg/day for 21/28 ...
Show more >Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25 mg/day for 21/28 days, the highest possible dose, in Waldenström's Macroglobulinemia (WM). We aimed to determine the maximum tolerated dose (MTD) of single agent lenalidomide and determine its impact on WM. RV-WM-0426 is a multicenter dose escalation open label phase 1/2 study of lenalidomide in relapsed/refractory WM (RRWM). Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD. Seventeen RRWM patients were included. The MTD was established at 15 mg/day 21/28. By ITT analysis, the overall response rate was 29%. With a median follow-up of 36 months, median TTP was 16 months (95% CI 5.5-26), the 5-year OS was 91%. The most frequent adverse events ≥ grade 3 at 15 mg were 14% anemia and 43% neutropenia. The MTD of lenalidomide is 15 mg/day 21/28 days in RRWM. Lenalidomide is active in the treatment of RRWM and the safety profile appears manageable. Future studies may look into combinations of lenalidomide and continuous dosing.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:52:33Z